Federal Center of Nuclear Medicine Project Design and Development
We are constantly working to create and improve high-tech products and services in the field of nuclear medicine.
Perspectives for development
Our experts conduct scientific research and development using the latest technologies to achieve maximum efficiency and safety for patients and medical staff.
The principle of radionuclide cancer therapy is the introduction into the human body of special medications that contain radionuclides. Such drugs reach the affected areas directly, so the radiation is targeted (does not affect the entire body, but acts specifically on cancer sites).
The drug that is administered to the patient during radionuclide treatment accumulates in the affected area: the primary tumor or metastases. It irradiates the tumor, leading to its destruction. Surrounding tissues, healthy structures and the entire body are minimally affected.
Radium chloride, 223 Ra, solution for intravenous administration
Intended for radionuclide therapy of bone metastases in castration – resistant prostate cancer and the absence of visceral metastases.
177Lu-DOTATATE, solution for intravenous administration.
Radionuclide therapy of neuroendocrine tumors.
Hepatoren – MRNC, suspension for intra-arterial administration.
Intended for radioembolization of hepatocarcinoma and liver metastases. *Joint development project with MRRC named after Tsyba, that is a branch of the National Medical Research Center of Radiology of the Ministry of health of the Russian Federation
Artroren- MRNC*, suspension for intra-articular admistration.
For radiosynovectomy of joint diseases. *Joint development project with MRRC named after Tsyba, that is a branch of the National Medical Research Center of Radiology of the Ministry of health of the Russian Federation